




Regulatory and reimbursement issues aside, what would you generally recommend as second-line therapy for a patient with metastatic UBC whose disease progresses on first-line cisplatin/gemcitabine?



Based on available data and your own clinical experience, do you believe there are any clinically meaningful differences in the efficacy and tolerability of the five approved anti-PD-1/anti-PD-L1 antibodies?




Which first-line therapy would you recommend for a 78-year-old patient with metastatic UBC who is not a candidate for cisplatin-based chemotherapy?




Which first-line therapy would you recommend for a 78-year-old patient with metastatic UBC who is not a candidate for platinum-based chemotherapy?



Erdafitinib is approved for use in patients with metastatic UBC with a susceptible _____ genetic alteration who have progressed on or after chemotherapy.



A recent study demonstrated that more than one third of patients with high-risk nonmuscle-invasive UBC unresponsive to BCG experienced a complete response to anti-PD-1/PD-L1 antibody therapy.



Which first-line therapy would you recommend for a 78-year-old patient with metastatic UBC who is not a candidate for cisplatin-based chemotherapy?

